Grown Rogue International (GRUSF) Income from Continuing Operations (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Income from Continuing Operations came in at 2213391.0 in Q1 2026, down 397.95% year-on-year from 742870.0 in Q1 2025, and up 100.0% quarter-over-quarter from 5914428696762.0 in Q4 2025.
Grown Rogue International (GRUSF) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Grown Rogue International's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 2213391.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 397.95% year-over-year to 2213391.0 in Q1 2026; TTM through Mar 2026 was 3002472239218.0, a 126.75% decrease from a year earlier, with the FY2025 full-year figure at 2116762.0, down 164.78% from the prior year.
- Income from Continuing Operations advanced to 2213391.0 in Q1 2026 per GRUSF's latest filing, from 5914428696762.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11224874723495.0 in Q4 2024 and bottomed at 5914428696762.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 192459.0 (2022), against an average of 548159551111.95.
- Across the five-year window, Income from Continuing Operations surged 1062995946.79% in 2024 and sank 397.95% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 192459.0 in 2022, then plunged by 648.67% to 1055966.0 in 2023, then jumped by 1062995946.79% to 11224874723495.0 in 2024, then slumped by 152.69% to 5914428696762.0 in 2025, then surged by 100.0% to 2213391.0 in 2026.
- Per Business Quant, the three latest GRUSF Income from Continuing Operations figures stand at 2213391.0 (Q1 2026), 5914428696762.0 (Q4 2025), and 2911957000000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Grown Rogue International | 99.32 Mn | 85.61 Mn | 3.96 Mn | -2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.21 Mn |
| Dec 31, 2025 | -5,914.43 Bn |
| Sep 30, 2025 | 2,911.96 Bn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 742,870.00 |
| Dec 31, 2024 | 11,224.87 Bn |
| Sep 30, 2024 | -299,348.22 |
| Jun 30, 2024 | -5.13 Mn |
| Mar 31, 2024 | -3.80 Mn |
| Dec 31, 2023 | -1.06 Mn |
| Oct 31, 2023 | -1.49 Mn |
| Jul 31, 2023 | 319,315.16 |
| Apr 30, 2023 | 631,938.00 |
| Jan 31, 2023 | 667,291.00 |
| Jan 31, 2022 | 192,459.00 |
| Oct 31, 2021 | 1.62 Mn |
| Jul 31, 2021 | 764,360.00 |
| Apr 30, 2021 | -586,589.00 |
| Jan 31, 2021 | -995,593.00 |
| Oct 31, 2020 | -3.55 Mn |